Jennifer Chow

Company: iCell Gene Therapeutics

Job title: Chief Executive Officer

Bio:

Jennifer Chow is a pioneer in cell therapy, having led the launch of over 10 oncology therapeutics, including key CAR T cell therapies like Ide-cel, Liso-cel, Axi-cel, and Brexu-cel. She held leadership roles at Celgene, Kite (Gilead), and served as CEO of Chimeric Therapeutics. Now at iCell Gene Therapeutics, she is advancing innovative cell therapies for autoimmune diseases and cancer to address critical patient needs.

Seminars:

Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy 3:30 pm

Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patientsRead more

day: Conference Day One P3

Industry Leaders Fireside Chat: Evaluating CAR-T in Comparison to Emerging Modalities to Refine Autoimmune Therapies Through Strategic Modality Selection 8:40 am

Explore the efficacy of differing modalities to identify opportunities where we can learn from other modalities Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety Identify autoimmune indications where CD-19-CARs are suboptimal to spotlight opportunities for alternative therapeutic modalitiesRead more

day: Conference Day 1 P1